- Home
- RCS vs RCKT Comparison
RCS vs RCKT Comparison
Compare RCS & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | RCKT |
|---|---|---|
| Founded | 1994 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.4M | 239.3M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RCS | RCKT |
|---|---|---|
| Price | $5.01 | $2.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $8.58 |
| AVG Volume (30 Days) | 133.7K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $915.60 |
| P/E Ratio | ★ N/A | $3.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.84 | $2.17 |
| 52 Week High | $7.17 | $5.45 |
Technical Indicators
Market Signals| Indicator | RCS | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 47.85 |
| Support Level | $4.87 | $2.17 |
| Resistance Level | $5.67 | $2.73 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 57.14 | 64.00 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with their objective.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.